Status:
COMPLETED
Dosing Chart for Calculating the First Dose of Doxapram in Premature Infants
Lead Sponsor:
Jean Michel Hascoet
Conditions:
Premature Infants
Apnea
Eligibility:
All Genders
1-3 years
Phase:
PHASE4
Brief Summary
Doxapram is used to stimulate respiration. For a given dose, the fluctuations in concentrations observed in infants' blood may be wide, leading to a risk of lack of efficacy or of toxic effects. Two f...
Detailed Description
Doxapram is a drug used to stimulate respiration in neonates prematurely born and failing to breathe. For a given dose, the fluctuations in concentrations of drug observed in infants' blood might be w...
Eligibility Criteria
Inclusion
- Premature infants (\<37 weeks gestation)
- More than 1 significant Apnea q 8h (\> 20 sec or \< 20 sec with bradycardia or desaturation)
- Already treated with caffeine
Exclusion
- Intubation
- congenital malformation
- symptomatic apnea
Key Trial Info
Start Date :
November 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2010
Estimated Enrollment :
85 Patients enrolled
Trial Details
Trial ID
NCT00389909
Start Date
November 1 2006
End Date
November 1 2010
Last Update
February 27 2017
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Maternite Regionale Universitaire
Nancy, France, 54042
2
Hopital des Enfants
Toulouse, France, 31059